Hepatitis C virus

Hepatitis C virus

MATERIAL SAFETY DATA SHEET - INFECTIOUS SUBSTANCES

SECTION I - INFECTIOUS AGENT

NAME: Hepatitis C virus

SYNONYM OR CROSS REFERENCE: Parenterally transmitted non-A, non-B hepatitis, Non-B transfusion-associated hepatitis, Post-transfusion non-A, non-B hepatitis (PT-NANB), HCV

CHARACTERISTICS: Single stranded, small, positive sense RNA, enveloped, 50 nm diameter, Flaviviridae

SECTION II - HEALTH HAZARD

PATHOGENICITY: Onset is insidious, with anorexia, vague abdominal discomfort, nausea and vomiting, progressing to jaundice (less frequently than hepatitis B); severity ranges from unapparent cases in approximately 90% of infections to rare fulminating, fatal cases; chronic liver disease with fluctuating or persistently elevated liver enzymes is common, occurring after 50%-80% of HCV infections in adults; of those with chronic liver disease, 30%-60% may develop chronic active hepatitis and 5%-20% may develop cirrhosis; chronic infection is often not symptomatic; there appears to be an association between HCV infection and hepatocellular carcinoma, of these chronically infected persons, approximately 50% will develop cirrhosis or cancer of the liver

EPIDEMIOLOGY: HCV has been found in every part of the world where it has been sought; the virus is parenterally transmitted; in the United States, HCV accounts for about 20% of acute viral hepatitis cases, of which less than 5% are associated with blood transfusion; prevalence of anti-HCV is highest in injecting drug users and hemophilia patients (70%-90%), moderate in hemodialysis patients (10%-20%), low in heterosexuals with multiple sex partners, homosexual men, health care workers and family contacts of HCV-infected persons (1%-5%), and lowest in volunteer blood donors (0.3%-0.5%); major cause of parenterally transmitted non A, non B hepatitis

HOST RANGE: Humans; has been experimentally transmitted to chimpanzees

INFECTIOUS DOSE: Not known

MODE OF TRANSMISSION: Percutaneous exposure to contaminated blood (102 - 103 infectious particles / mL of blood) and plasma derivatives; contaminated needles and syringes are important vehicles of spread, especially among injecting drug users; risk of HCV transmission by household contact and sexual activity has not been well defined, but efficiency of transmission via these routes appears to be low; vertical transmission appears to be uncommon, however risk of transmission may increase when the mother is co-infected with HIV; in over 40% of cases, the risk factor(s) for HCV transmission cannot be identified

INCUBATION PERIOD: Ranges from 2 weeks to 6 months; most commonly 7 - 10 weeks; chronic infection may persist for up to 20 years before onset of cirrhosis or heptoma

COMMUNICABILITY: From one or more weeks before onset of first symptoms; may persist in most persons indefinitely

SECTION III - DISSEMINATION

RESERVOIR: Humans. Other reservoirs are unknown in the current literature

ZOONOSIS: Not known

VECTORS: Not known

SECTION IV - VIABILITY

DRUG SUSCEPTIBILITY: No specific antivirals

SUSCEPTIBILITY TO DISINFECTANTS: The data available in the current literature on the susceptibility of HCV to disinfectants are limited. Therefore, because HCV is an enveloped virus, general disinfection measures against hepatitis B virus are applicable to HCV (1% sodium hypochlorite, 70% ethanol, 2% glutaraldehyde, formaldehyde).

PHYSICAL INACTIVATION: The data available in the current literature on the susceptibility of HCV to physical inactivation are limited. Again, because HCV is an enveloped virus, general inactivation measures against hepatitis B virus are applicable to HCV (stable at 37°C for 60 min but not at temperatures above 60°C; stable at pH 2.4 for up to 6 hours). May not be inactivated by UV.

SURVIVAL OUTSIDE HOST: Not known. Suspected to be similar to hepatitis B virus (survives in dried blood for long periods-weeks)

SECTION V - MEDICAL

SURVEILLANCE: Testing of blood samples for elevated liver enzyme levels, anti-HCV or direct viral RNA detection by PCR amplification

FIRST AID/TREATMENT: Interferon alpha has been shown to have an overall beneficial effect in about 25% of chronic hepatitis cases; a combined treatment of ribavirin-interferon alpha has been reported to be equally effective or better than alpha interferon alone for treatment of chronic hepatitis

IMMUNIZATION: Applicability of immunization not known; repeated infections with HCV have been demonstrated in an experimental chimpanzee model

PROPHYLAXIS: None available

SECTION VI - LABORATORY HAZARDS

LABORATORY-ACQUIRED INFECTIONS: Medical personnel have slightly higher antibody prevalence to HCV than the general population; therefore health care workers handling blood are at higher risk to HCV infection, however, not to the same degree as HBV infection

SOURCES/SPECIMENS: Blood and blood products. Transmission through sexual and casual contact is not well documented

PRIMARY HAZARDS: Parenteral inoculation of blood and plasma products. However, over half of HCV infections in the United States are due to factors other than percutaneous exposure to HCV. These other factors are yet unknown

SPECIAL HAZARDS: Needle stick with infected blood

SECTION VII - RECOMMENDED PRECAUTIONS

CONTAINMENT REQUIREMENTS: Containment level 2 practices for activities utilizing infectious body fluids and tissues; Containment level 3 and personnel precautions for activities with high potential for droplet or aerosol production and high production quantities or concentrations; Animal Pathogen containment level 2 for work with non-human primates

PROTECTIVE CLOTHING: Laboratory coat; gloves when skin contact is unavoidable and when working with animals; wrap-around gown and gloves for work in biosafety cabinet

OTHER PRECAUTIONS: General needle safety precautions important - do not bend, break or recap needles; dispose directly into puncture-proof container; universal precautions for blood

SECTION VIII - HANDLING INFORMATION

SPILLS: Allow aerosols to settle; wearing protective clothing, gently cover spill with absorbent paper towel and apply 1% sodium hypochlorite (effective for HBV), starting at perimeter and working towards the centre; allow sufficient contact time (30 min-effective for HBV) before clean-up

DISPOSAL: Decontaminate before disposal; steam sterilization, chemical disinfection, incineration

STORAGE: In sealed containers that are properly labelled

SECTION IX - MISCELLANEOUS INFORMATION

Date prepared: June, 2001

Prepared by: Office of Laboratory Security, PHAC

Although the information, opinions and recommendations contained in this Material Safety Data Sheet are compiled from sources believed to be reliable, we accept no responsibility for the accuracy, sufficiency, or reliability or for any loss or injury resulting from the use of the information. Newly discovered hazards are frequent and this information may not be completely up to date.

Copyright © Health Canada, 2001

This MSDS / PSDS document, provided by Public Health Agency of Canada (PHAC), is offered here as a FREE public service to visitors of MSDSonline. As outlined in this site’s Terms of Use, MSDSonline is not responsible for the accuracy, content or any aspect of the information contained therein.